NCT03784014 2025-12-11MULTISARCInstitut National de la Santé Et de la Recherche Médicale, FrancePhase 3 Active not recruiting603 enrolled
NCT03742349 2025-05-18Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).NovartisPhase 1 Terminated64 enrolled
NCT02414139 2024-03-20Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)NovartisPhase 2 Completed373 enrolled 34 charts 5 FDA
NCT03240393 2018-07-26Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)NovartisPhase 2 Withdrawn
NCT01072266 2017-11-22A Dose-escalation Study in Subjects With Advanced MalignanciesIncyte CorporationPhase 1 Completed45 enrolled